SG11201702614SA - Polysaccharide and nucleic acid formulations containing viscosity-lowering agents - Google Patents

Polysaccharide and nucleic acid formulations containing viscosity-lowering agents

Info

Publication number
SG11201702614SA
SG11201702614SA SG11201702614SA SG11201702614SA SG11201702614SA SG 11201702614S A SG11201702614S A SG 11201702614SA SG 11201702614S A SG11201702614S A SG 11201702614SA SG 11201702614S A SG11201702614S A SG 11201702614SA SG 11201702614S A SG11201702614S A SG 11201702614SA
Authority
SG
Singapore
Prior art keywords
polysaccharide
nucleic acid
formulations containing
lowering agents
acid formulations
Prior art date
Application number
SG11201702614SA
Inventor
Alyssa M Larson
Kevin Love
Alisha K Weight
Alan Crane
Robert S Langer
Alexander M Klibanov
Original Assignee
Eagle Biolog Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eagle Biolog Inc filed Critical Eagle Biolog Inc
Publication of SG11201702614SA publication Critical patent/SG11201702614SA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/722—Chitin, chitosan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/734—Alginic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG11201702614SA 2014-10-01 2015-09-30 Polysaccharide and nucleic acid formulations containing viscosity-lowering agents SG11201702614SA (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462058125P 2014-10-01 2014-10-01
US201462058124P 2014-10-01 2014-10-01
US201462058122P 2014-10-01 2014-10-01
US201462058123P 2014-10-01 2014-10-01
PCT/US2015/053313 WO2016054259A1 (en) 2014-10-01 2015-09-30 Polysaccharide and nucleic acid formulations containing viscosity-lowering agents

Publications (1)

Publication Number Publication Date
SG11201702614SA true SG11201702614SA (en) 2017-04-27

Family

ID=55631454

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201702614SA SG11201702614SA (en) 2014-10-01 2015-09-30 Polysaccharide and nucleic acid formulations containing viscosity-lowering agents
SG10201902915VA SG10201902915VA (en) 2014-10-01 2015-09-30 Polysaccharide and nucleic acid formulations containing viscosity-lowering agents

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201902915VA SG10201902915VA (en) 2014-10-01 2015-09-30 Polysaccharide and nucleic acid formulations containing viscosity-lowering agents

Country Status (11)

Country Link
US (1) US11471479B2 (en)
EP (1) EP3200804A4 (en)
JP (1) JP6716577B2 (en)
KR (1) KR102497368B1 (en)
CN (1) CN106999510B (en)
AU (1) AU2015325055B2 (en)
CA (1) CA2962768C (en)
IL (1) IL251390B (en)
MX (1) MX2017004306A (en)
SG (2) SG11201702614SA (en)
WO (1) WO2016054259A1 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2959451T3 (en) * 2013-09-11 2024-02-26 Eagle Biologics Inc Liquid protein formulations containing organophosphates
US10478498B2 (en) 2014-06-20 2019-11-19 Reform Biologics, Llc Excipient compounds for biopolymer formulations
US11357857B2 (en) 2014-06-20 2022-06-14 Comera Life Sciences, Inc. Excipient compounds for protein processing
US20160074515A1 (en) 2014-06-20 2016-03-17 Reform Biologics, Llc Viscosity-reducing excipient compounds for protein formulations
RU2612014C1 (en) * 2015-10-19 2017-03-01 Общество с ограниченной ответственностью "ДИАМЕД-фарма" Agent for treatment of arthrologic diseases
CA3053909A1 (en) * 2017-02-16 2018-08-23 Reform Biologics, Llc Excipient compounds for protein processing
US10646569B2 (en) 2017-05-16 2020-05-12 Bhami's Research Laboratory, Pvt. Ltd. High concentration protein formulations with reduced viscosity
KR102101384B1 (en) * 2017-11-02 2020-04-16 연세대학교 산학협력단 Pharmaceutical composition for treating or preventing ischemic cardiovascular disease
CN111918644A (en) * 2017-11-17 2020-11-10 哈佛大学校长及研究员协会 Ionic liquids for internal delivery
KR102056144B1 (en) * 2018-03-08 2019-12-16 주식회사 파마리서치프로덕트 Fluid composition containing higher concentrations of fragmented DNA mixtures and a method for manufacturing the same
US11655210B2 (en) 2018-05-18 2023-05-23 The General Hospital Corporation Compound for improving L-arginine bioavailability
US11365405B2 (en) 2019-03-20 2022-06-21 Anchor Molecular Inc. Method of removing nucleic acids from human plasma
EP3957977B1 (en) * 2019-04-18 2023-08-30 Fundació Institut de Ciències Fotòniques Fluidic apparatus for optical interrogation of individual microorganisms
WO2021097228A1 (en) * 2019-11-13 2021-05-20 The General Hospital Corporation Compositions and salts for improving l-arginine bioavailability
US11684594B2 (en) 2020-05-12 2023-06-27 President And Fellows Of Harvard College Antifungal prophylaxis for cornea
CN112458001B (en) * 2020-07-30 2022-09-27 上海交通大学 Bacterial strain capable of degrading polycyclic aromatic hydrocarbon and application thereof
US20240024092A1 (en) * 2022-07-22 2024-01-25 SpyGlass Pharma, Inc. Intraocular drug delivery systems and methods of use
WO2024028218A1 (en) * 2022-08-01 2024-02-08 Merck Patent Gmbh Viscosity reducing excipients and combinations thereof for highly concentrated nucleic acid compositions
WO2024089094A1 (en) * 2022-10-26 2024-05-02 Dsm Ip Assets B.V. Preparation and compositions comprising saccharides and amino acids, and use thereof

Family Cites Families (162)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB750373A (en) 1953-01-15 1956-06-13 Pfizer & Co C Improvements in or relating to injectable suspension of penicillin salts
DK128416B (en) 1964-08-13 1974-04-29 Ciba Geigy Ag Analogous process for the preparation of adrenocorticotropically active nonadecapeptide amides or acid addition salts or complex compounds thereof.
BE757195A (en) 1969-10-07 1971-03-16 Century Disposable Devices SYRINGE FOR INJECTING A FRESHLY PREPARED MIXTURE OF POWDER AND LIQUID
JPS5270014A (en) 1975-12-05 1977-06-10 Senju Pharma Co Stabilization of pyrido*3*22a*phenoxadine compounds
US4171698A (en) 1977-08-15 1979-10-23 Abbott Laboratories Prefilled two-compartment syringe
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5521063A (en) 1985-03-15 1996-05-28 Antivirals Inc. Polynucleotide reagent containing chiral subunits and methods of use
US5166315A (en) 1989-12-20 1992-11-24 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
ATE171185T1 (en) 1985-03-15 1998-10-15 Antivirals Inc POLYNUCLEOTIDE IMMUNOTESTING AGENTS AND METHODS
US5506337A (en) 1985-03-15 1996-04-09 Antivirals Inc. Morpholino-subunit combinatorial library and method
US5217866A (en) 1985-03-15 1993-06-08 Anti-Gene Development Group Polynucleotide assay reagent and method
AU4128089A (en) 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
US5001000A (en) 1988-09-26 1991-03-19 E. I. Du Pont De Nemours And Company Process for forming a composite structure of thermoplastic polymer and sheet molding compound
US5114703A (en) * 1989-05-30 1992-05-19 Alliance Pharmaceutical Corp. Percutaneous lymphography using particulate fluorocarbon emulsions
US5730978A (en) 1989-09-01 1998-03-24 Fred Hutchinson Cancer Research Center Inhibition of lymphocyte adherence with α4β1-specific antibodies
US6033665A (en) 1989-09-27 2000-03-07 Elan Pharmaceuticals, Inc. Compositions and methods for modulating leukocyte adhesion to brain endothelial cells
JPH03190823A (en) 1989-12-21 1991-08-20 Snow Brand Milk Prod Co Ltd Erythropoietin hypodermic or intramuscular administration agent
US5698195A (en) 1991-03-18 1997-12-16 New York University Medical Center Methods of treating rheumatoid arthritis using chimeric anti-TNF antibodies
US5714331A (en) 1991-05-24 1998-02-03 Buchardt, Deceased; Ole Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
US5539082A (en) 1993-04-26 1996-07-23 Nielsen; Peter E. Peptide nucleic acids
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
US5356802A (en) 1992-04-03 1994-10-18 The Johns Hopkins University Functional domains in flavobacterium okeanokoites (FokI) restriction endonuclease
US5487994A (en) 1992-04-03 1996-01-30 The Johns Hopkins University Insertion and deletion mutants of FokI restriction endonuclease
US5436150A (en) 1992-04-03 1995-07-25 The Johns Hopkins University Functional domains in flavobacterium okeanokoities (foki) restriction endonuclease
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
DE69419721T2 (en) 1993-01-12 2000-04-27 Biogen Inc RECOMBINANT ANTI-VLA4 ANTIBODY MOLECULES
US5334162A (en) 1993-03-15 1994-08-02 Eli Lilly And Company Cartridge assembly for a lyophilized compound forming a disposable portion of an injector pen and method for same
US5744155A (en) * 1993-08-13 1998-04-28 Friedman; Doron Bioadhesive emulsion preparations for enhanced drug delivery
US5527675A (en) 1993-08-20 1996-06-18 Millipore Corporation Method for degradation and sequencing of polymers which sequentially eliminate terminal residues
DE4331012A1 (en) 1993-09-13 1995-03-16 Bayer Ag Nucleic acid-binding oligomers with N-branching for therapy and diagnostics
DE4344824C1 (en) 1993-12-28 1995-08-31 Immuno Ag Highly concentrated immunoglobulin preparation and process for its preparation
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
GB9418092D0 (en) 1994-09-08 1994-10-26 Red Cross Found Cent Lab Blood Organic compounds
JP3524974B2 (en) 1994-12-26 2004-05-10 ブラッコ インターナショナル ビーヴィ Prefilled syringe and package thereof
US5569193A (en) 1995-03-22 1996-10-29 Abbott Laboratories Syringe system accommodating separately storable prefilled containers for two constituents
US5779668A (en) 1995-03-29 1998-07-14 Abbott Laboratories Syringe barrel for lyophilization, reconstitution and administration
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
DE19617369A1 (en) 1996-04-30 1997-11-06 Immuno Ag Storage-stable fibrinogen preparations
US6184037B1 (en) 1996-05-17 2001-02-06 Genemedicine, Inc. Chitosan related compositions and methods for delivery of nucleic acids and oligonucleotides into a cell
GB9610992D0 (en) 1996-05-24 1996-07-31 Glaxo Group Ltd Concentrated antibody preparation
US5819998A (en) 1996-09-30 1998-10-13 Everything Kids Knapsack with simulated basketball court
IN184589B (en) 1996-10-16 2000-09-09 Alza Corp
US5819988A (en) 1997-04-01 1998-10-13 Sawhney; Ravi K. Double-barreled syringe with detachable locking mixing tip
US6065645A (en) 1997-04-01 2000-05-23 Discus Dental Impressions, Inc. Double-barreled syringe with detachable locking mixing tip
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US5786571A (en) 1997-05-09 1998-07-28 Lexmark International, Inc. Wrapped temperature sensing assembly
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
AU729876B2 (en) 1997-10-15 2001-02-15 Asahi Kasei Kabushiki Kaisha Method for maintaining the quality of aqueous injection preparation of thrombomodulin over its storage/transportation
ATE357658T1 (en) 1997-10-22 2007-04-15 Chugai Pharmaceutical Co Ltd METHOD FOR SCREENING TGF-BETA INHIBITING SUBSTANCES
US7919109B2 (en) 1999-02-08 2011-04-05 Intarcia Therapeutics, Inc. Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
FR2794649B1 (en) * 1999-06-11 2003-04-11 Solutions BIOMATERIAL BASED ON AN INSOLUBILIZED DEXTRAN DERIVATIVE AND A GROWTH FACTOR, METHOD FOR PREPARING SAME AND ITS APPLICATIONS
AUPQ132599A0 (en) * 1999-07-01 1999-07-22 Commonwealth Scientific And Industrial Research Organisation Nasogastric enteral formulations
US7030097B1 (en) 1999-07-14 2006-04-18 Cornell Research Foundation, Inc. Controlled nucleic acid delivery systems
EP1072323B1 (en) 1999-07-29 2003-09-10 Wilhelm A. Keller Cartridge discharge device with actuator for dynamic mixers
CZ20021186A3 (en) 1999-10-04 2002-11-13 Chiron Corporation Pharmaceutical preparations containing stabilized liquid polypeptide
US6394314B1 (en) 1999-10-12 2002-05-28 Discus Dental Impressions, Inc. Double-barreled syringe with detachable locking mixing tip
US6443612B1 (en) 1999-12-02 2002-09-03 Wilhelm A. Keller Dynamic mixer
AU2002213441B2 (en) 2000-10-12 2006-10-26 Genentech, Inc. Reduced-viscosity concentrated protein formulations
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
JP4434583B2 (en) 2000-11-30 2010-03-17 バイオバルブ テクノロジーズ インコーポレイテッド Injection system
EP1873259B1 (en) 2000-12-01 2012-01-25 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. RNA interference mediated by 21 and 22nt RNAs
WO2002092014A2 (en) 2001-05-16 2002-11-21 Biomarin Pharmaceutical Inc. Destruction of prions using vibriolysin or variants thereof
GB0113179D0 (en) 2001-05-31 2001-07-25 Novartis Ag Organic compounds
MXPA04000747A (en) 2001-07-25 2004-07-08 Protein Desing Labs Inc Stable lyophilized pharmaceutical formulation of igg antibodies.
BR0211579A (en) 2001-08-02 2004-07-13 3M Innovative Properties Co Glass-ceramic, beads, plurality of abrasive particles, abrasive article, and methods for abrading a surface, for making glass-ceramic, for making a glass-ceramic article, and for making abrasive particles
JP4167820B2 (en) 2001-10-19 2008-10-22 アルインコ株式会社 Deck plate traveling cart
GB0212405D0 (en) 2002-05-29 2002-07-10 Insignion Holdings Ltd Composition and its therapeutic use
US9415102B2 (en) 2002-09-06 2016-08-16 Alexion Pharmaceuticals, Inc. High concentration formulations of anti-C5 antibodies
WO2004055164A2 (en) 2002-12-13 2004-07-01 Abgenix, Inc. System and method for stabilizing antibodies with histidine
PL2405015T3 (en) 2003-03-05 2016-09-30 Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
JP2006522133A (en) 2003-03-31 2006-09-28 アルザ・コーポレーション Non-aqueous single phase media and formulations utilizing such media
PL2335725T3 (en) 2003-04-04 2017-04-28 Genentech, Inc. High concentration antibody and protein formulations
US20050158303A1 (en) 2003-04-04 2005-07-21 Genentech, Inc. Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations
WO2005030119A2 (en) 2003-04-11 2005-04-07 Allergan, Inc. Botulinum toxin a peptides and methods of predicting and reducing immunoresistance to botulinum toxin therapy
EP1616004A1 (en) 2003-04-15 2006-01-18 Ista Pharmaceuticals, Inc Process for isolating and purifing ovine hyaluronidase
US20040247672A1 (en) * 2003-05-16 2004-12-09 Alkermes Controlled Therapeutics, Inc. Injectable sustained release compositions
US20070184084A1 (en) * 2003-05-30 2007-08-09 Guohua Chen Implantable elastomeric caprolactone depot compositions and uses thereof
MXPA05014171A (en) * 2003-06-23 2007-02-21 Sanofi Pasteur Inc Immunization method against neisseria meningitidis.
CN1206344C (en) * 2003-07-28 2005-06-15 中国海洋大学 Method for producing fucan sulfatase by means of bacteria
GB0327723D0 (en) * 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
JP2007523050A (en) 2003-09-17 2007-08-16 カイアズマ・リミテッド Composition that can facilitate permeation through biological barriers
EP1532983A1 (en) 2003-11-18 2005-05-25 ZLB Bioplasma AG Immunoglobulin preparations having increased stability
GB0403938D0 (en) * 2004-02-21 2004-03-24 West Pharm Serv Drug Res Ltd Chitosan containing solution
ATE469191T1 (en) 2004-11-25 2010-06-15 Chr Hansen As METHOD FOR PRODUCING A CARMINAL ACID LACQUER
US20060141040A1 (en) 2004-12-23 2006-06-29 Guohua Chen Injectable non-aqueous suspension
US20060142234A1 (en) 2004-12-23 2006-06-29 Guohua Chen Injectable non-aqueous suspension
EP1931760A4 (en) 2005-10-07 2010-10-20 Univ Alabama Multi-functional ionic liquid compositions
CN100416002C (en) 2005-10-26 2008-09-03 曲新华 Sewage recycling apparatus
AR058567A1 (en) 2005-12-20 2008-02-13 Bristol Myers Squibb Co FORMULATIONS OF STABLE PROTEINS
US9309316B2 (en) 2005-12-20 2016-04-12 Bristol-Myers Squibb Company Stable subcutaneous protein formulations and uses thereof
EP1962907A2 (en) 2005-12-21 2008-09-03 Wyeth a Corporation of the State of Delaware Protein formulations with reduced viscosity and uses thereof
WO2007074880A1 (en) 2005-12-28 2007-07-05 Chugai Seiyaku Kabushiki Kaisha Antibody-containing stabilizing preparation
CA2638811A1 (en) 2006-02-03 2007-08-16 Medimmune, Llc Protein formulations
DE102006005094A1 (en) 2006-02-04 2007-08-09 Degussa Gmbh Titanium dioxide and polycarboxylate ether-containing dispersion
ITMI20061030A1 (en) * 2006-05-26 2007-11-27 Altergon Sa NEW COMPOSITION INCLUDING GLYCOSAMINOGLICANS WITH CONTROLLED VISCOSITY AND USE OF SUCH COMPOSITION IN THE THERAPY OF CHRONIC CYSTITIS
CU23526B6 (en) 2006-10-03 2010-05-19 Ct Ingenieria Genetica Biotech METHOD FOR MORFOFUNCTIONAL RESTORATION OF PERIPHERAL NERVES IN DIABETIC NEUROPATHY
US20090022727A1 (en) 2007-01-26 2009-01-22 Alza Corp. Injectable, nonaqueous suspension with high concentration of therapeutic agent
CA2688415C (en) 2007-05-31 2015-11-10 Anterios, Inc. Nucleic acid nanoparticles and uses therefor
WO2009015367A2 (en) 2007-07-25 2009-01-29 Arizona Board Of Regents For And On Behalf Of Arizona State University Stabilizing proteins using ionic liquids
WO2009026122A1 (en) 2007-08-17 2009-02-26 Amgen Inc. Formulations of antibodies and fc-fusion molecules using polycations
CA2701032C (en) 2007-09-27 2021-01-26 Amgen Inc. Pharmaceutical formulations
US8552046B2 (en) * 2007-10-16 2013-10-08 Pharmacyclics, Inc. Manufacture, compositions and uses of coagulation factor VIIa modulator
WO2009064838A1 (en) 2007-11-15 2009-05-22 Amgen, Inc. Aqueous formulation of erythropoiesis stimulating protein stablised by antioxidants for parenteral administration
EP2234636A4 (en) 2007-12-21 2013-05-15 Lyotropic Therapeutics Inc Stabilized formulations of peptides and proteins
PE20091174A1 (en) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd LIQUID FORMULATION WITH HIGH CONCENTRATION OF ANTIBODY CONTENT
WO2009120684A1 (en) 2008-03-25 2009-10-01 Medimmune, Llc Antibody formulation
WO2009137471A2 (en) 2008-05-05 2009-11-12 University Of Miami Azo dye related small molecule modulators of protein-protein interactions
EP2123307A1 (en) 2008-05-20 2009-11-25 Hexal Ag Method for reducing leachables and extractables in syringes
CA2743789C (en) 2008-11-16 2017-10-31 Board Of Regents, The Univesity Of Texas System Low viscosity highly concentrated suspensions
TWI342781B (en) 2008-12-01 2011-06-01 Univ China Medical Blood sugar-modulating polypeptides
AU2010221156A1 (en) 2009-03-06 2011-09-22 Genentech, Inc. Antibody formulation
WO2010132047A1 (en) 2009-05-14 2010-11-18 Rensselaer Polytechnic Institute Guanosine/gmp gels and uses thereof
US20120064553A1 (en) 2009-05-20 2012-03-15 Sekisui Medical Co., Ltd Blood coagulation time prolonging agent
EP3075386B1 (en) 2009-06-17 2019-10-16 BioMarin Pharmaceutical Inc. Formulations for lysosomal enzymes
RU2012108108A (en) 2009-08-04 2013-09-10 Дженентек, Инк. CONCENTRATED POLYPEPTIDE MEDICINAL FORMS WITH REDUCED VISCOSITY
DK2477603T3 (en) 2009-09-17 2016-06-13 Baxalta Inc STABLE CO-DEVELOPMENT OF hyaluronidase and Immunoglobulin, AND METHODS OF USE THEREOF
EP2491123B1 (en) 2009-10-20 2018-04-18 The Regents of The University of California Single molecule nucleic acid nanoparticles
UY32979A (en) 2009-10-28 2011-02-28 Abbott Lab IMMUNOGLOBULINS WITH DUAL VARIABLE DOMAIN AND USES OF THE SAME
PT3721904T (en) 2009-11-20 2021-11-15 Biocon Ltd Formulations of t1h antibody
US9289381B2 (en) 2009-12-03 2016-03-22 The University Of North Carolina At Charlotte Stabilization and storage of biological pharmaceutical compositions
PT2816112T (en) 2009-12-10 2018-11-20 Univ Iowa State Res Found Inc Tal effector-mediated dna modification
ES2522935T3 (en) 2010-01-08 2014-11-19 Chanel Parfums Beauté Use of at least one extract of Camellia japonica alba full flowers to moisturize the skin
AU2011212440B2 (en) 2010-02-04 2015-01-22 Csl Behring Ag Immunoglobulin preparation
CN107496917B (en) * 2010-02-26 2021-06-11 诺沃—诺迪斯克有限公司 Compositions comprising stable antibodies
SG184355A1 (en) 2010-03-01 2012-11-29 Progenics Pharm Inc Concentrated protein formulations and uses thereof
WO2011109415A2 (en) 2010-03-02 2011-09-09 Amgen Inc. Reducing viscosity of pharmaceutical formulations
US9072668B2 (en) 2010-03-09 2015-07-07 Janssen Biotech, Inc. Non-aqueous high concentration reduced viscosity suspension formulations of antibodies
RU2012144017A (en) 2010-03-17 2014-04-27 Эбботт Рисерч Б.В. COMPOSITIONS OF ANTIBODIES AGAINST NERVE GROWTH FACTOR (NGF)
CA2794631A1 (en) 2010-03-31 2011-10-06 Universite De Geneve Stabilized antibody preparations and uses thereof
CN101851267A (en) 2010-04-22 2010-10-06 江南大学 Antibody protective agent and application thereof
MX2012012743A (en) 2010-05-03 2012-11-23 Genentech Inc Compositions and methods useful for reducing the viscosity of protein-containing formulations.
GB201012179D0 (en) 2010-07-20 2010-09-01 Future Injection Technologies Injection device
US8936827B2 (en) * 2011-02-25 2015-01-20 Abbott Cardiovascular Systems Inc. Methods of loading a hollow stent with a drug or drug formulation
EP2694100A4 (en) 2011-04-07 2014-10-01 Glaxosmithkline Llc Formulations with reduced viscosity
CA2832560A1 (en) 2011-04-07 2012-10-18 Glaxosmithkline Llc Formulations with reduced viscosity
RU2618159C2 (en) * 2011-05-12 2017-05-02 БАЙЕР ХелсКер ЛЛСи System of liquid administration with different systems of injection procedure control
RU2485133C2 (en) 2011-05-30 2013-06-20 Закрытое Акционерное Общество "Фарм-Синтез" Protein-polypeptide complex possessing tissue-specific regenerative-reparative and rejuvenating action on skin tissue, method for preparing it, and pharmaceutical composition thereof
US9241869B2 (en) 2011-10-25 2016-01-26 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
KR101759694B1 (en) 2011-10-28 2017-07-19 인테그리티 바이오, 아이엔씨. Protein formulations containing amino acids
AR089434A1 (en) 2011-12-23 2014-08-20 Genentech Inc PROCEDURE TO PREPARE FORMULATIONS WITH HIGH CONCENTRATION OF PROTEINS
CA2899433A1 (en) 2012-01-27 2013-08-01 Gliknik Inc. Fusion proteins comprising igg2 hinge domains
JP6345123B2 (en) 2012-02-16 2018-06-20 サンタラス， インコーポレイテッド Anti-VLA1 (CD49A) antibody pharmaceutical composition
US9574193B2 (en) * 2012-05-17 2017-02-21 Ionis Pharmaceuticals, Inc. Methods and compositions for modulating apolipoprotein (a) expression
WO2013173789A2 (en) * 2012-05-17 2013-11-21 Isis Pharmaceuticals, Inc. Antisense oligonucleotide compositions
KR102201607B1 (en) 2012-05-18 2021-01-12 제넨테크, 인크. High-concentration monoclonal antibody formulations
RU2014152803A (en) * 2012-05-25 2016-07-20 Новартис Аг WATER PHARMACEUTICAL COMPOSITION CONTAINING A THERAPEUTIC AGENT AND GUANIDINE, GUANIDINE DERIVATIVE AND INJECTION INCLUDING THIS COMPOSITION
ES2960803T3 (en) 2012-05-25 2024-03-06 Univ California Methods and compositions for RNA-directed modification of target DNA and for modulation of RNA-directed transcription
MA37777B1 (en) 2012-06-21 2017-07-31 Ucb Pharma Sa Pharmaceutical preparation
CN116622704A (en) 2012-07-25 2023-08-22 布罗德研究所有限公司 Inducible DNA binding proteins and genomic disruption tools and uses thereof
RU2015107891A (en) 2012-08-09 2016-09-27 Роше Гликарт Аг ANTIBODIES TO ASGPR AND THEIR APPLICATION
FR2994390B1 (en) 2012-08-10 2014-08-15 Adocia METHOD FOR LOWERING THE VISCOSITY OF HIGH CONCENTRATION PROTEIN SOLUTIONS
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
FR2995214B1 (en) 2012-09-10 2014-11-21 Adocia REDUCED VISCOSITY SOLUTION OF HIGH CONCENTRATION PROTEIN
WO2014160083A1 (en) * 2013-03-13 2014-10-02 Applied Cardiovascular Solutions, Llc. Methods, compositions, and devices for the occlusion of cavities and passageways
US9669242B2 (en) 2013-07-01 2017-06-06 L'oreal Compositions containing at least two phenolic compounds, a lipid-soluble antioxidant and at least one hydrotrope for cosmetic use
ES2959451T3 (en) * 2013-09-11 2024-02-26 Eagle Biologics Inc Liquid protein formulations containing organophosphates
US20160074515A1 (en) 2014-06-20 2016-03-17 Reform Biologics, Llc Viscosity-reducing excipient compounds for protein formulations

Also Published As

Publication number Publication date
JP6716577B2 (en) 2020-07-01
CN106999510A (en) 2017-08-01
WO2016054259A1 (en) 2016-04-07
EP3200804A1 (en) 2017-08-09
CN106999510B (en) 2021-04-30
CA2962768C (en) 2023-10-10
KR102497368B1 (en) 2023-02-10
SG10201902915VA (en) 2019-04-29
JP2017530196A (en) 2017-10-12
US11471479B2 (en) 2022-10-18
KR20170078669A (en) 2017-07-07
CA2962768A1 (en) 2016-04-07
AU2015325055A1 (en) 2017-04-20
EP3200804A4 (en) 2018-04-18
IL251390A0 (en) 2017-05-29
IL251390B (en) 2022-01-01
US20180228831A1 (en) 2018-08-16
MX2017004306A (en) 2017-12-20
AU2015325055B2 (en) 2021-02-25

Similar Documents

Publication Publication Date Title
IL251390B (en) Polysaccharide and nucleic acid formulations containing viscosity-lowering agents
IL280941A (en) Modified double-stranded rna agents
HK1256225A1 (en) Oligonucleotide compositions and methods thereof
HK1255370A1 (en) Oligonucleotide compositions and methods thereof
SG11201605906UA (en) Muscle-specific nucleic acid regulatory elements and methods and use thereof
SG11201608503UA (en) Methods and compositions for modifying genomic dna
GB201408841D0 (en) Nucleic acid processing
ZA202005857B (en) Oligonucleotide compositions and methods of making the same
SG11201608217PA (en) Fatty acid composition and use thereof
IL260122A (en) Methods and compositions for nucleic acid assembly
EP3362578A4 (en) Methods of genomic evaluation in livestock
EP3212792A4 (en) Nucleic acid modifying agents and uses thereof
HK1232145A1 (en) Bifunctional compounds and use for reducing uric acid levels
EP3139741A4 (en) Methods and compositions comprising 10-hydroxy-2-decenoic acid
HUE044268T2 (en) Composition containing glycosaminoglycans and proteins
GB201511863D0 (en) Pharmaceutical compositions comprising hexaminolevulnic acid and methods of using the same
GB201408204D0 (en) Methods and compositions for identifying nucleic acids
GB201408205D0 (en) Methods and compositions for identifying nucleic acids
GB201408207D0 (en) Methods and compositions for identifying nucleic acids
GB201408203D0 (en) Methods and compositions for identifying nucleic acids